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Abstract 
Although Alzheimer´s dementia (AD) is not anymore characterised just by the accumulation and 
deposition of amyloid beta (Aβ) peptides and hyperphosphorylation of tau proteins within the brain, 
excessive Aβ42 deposition is still considered to play a major role in AD. Aβ are able to adopt many 
differently aggregate forms, including amyloid fibrils as well as nonfibrillar structures (soluble Aβ42 
oligomers). It is not well established which Aβ42 state is most responsible for AD or why. We wanted 
to verify, which effects Aβ42 oligomers and aggregated peptides have on gene expression, protein level 
and enzyme activity of insulin and amyloid precursor protein (APP) pathways in vitro. Human 
neuroblastoma cells (SH-SY5Y) were treated with varying concentrations of soluble and aggregated 
Aβ42. Treatment effects on -secretase (BACE), glycogen synthase kinase 3α (GSK3α), glycogen 
synthase kinase 3 (GSK3), phosphatidylinisitol-3 kinase (PI-3K), insulin degrading enzyme (IDE), 
insulin receptor substrate 1 (IRS1), insulin receptor (INSR) and monoamine oxidase B (MAO-B) was 
investigated via quantitative-PCR, western blot, ELISA and enzyme activity assay. We could find 
different effects of soluble and aggregated peptides especially on gene/ protein expression of GSK3β 
and INSR and on GSK3β and MAO-B activity. Soluble peptides showed significant effects leading to 
increased gene expression and protein amount of GSK3β and to decreased level of gene and protein 
expression of INSR. MAO-B activity was enhanced after treatment with aggregated peptides and 
strongly inhibited after soluble Aβ42 treatment. Our data might provide insights into selective effects of 
specific forms of A42 aggregates in AD. 
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Introduction  
Alzheimer´s dementia (AD) is not anymore characterised just by the accumulation and deposition of 
amyloid beta (Aβ) peptides and hyperphosphorylated tau proteins within the brain; in the mean time, it 
is also characterised by synaptic loss (Small, 2004), imbalanced metabolism (Schindowski et al., 2008; 
Grünblatt et al., 2010), abnormal protein cross-linking (Munch et al., 1998; Wang et al., 2008), and 
disturbance of the insulin signalling pathway (Hoyer et al., 1994; de la Monte et al., 2009; Riederer et 
al., 2010). Although more and more factors are found to be involved in AD, excessive Aβ42 deposition 
is still considered to play a major role in AD. However, the mechanisms that contribute to abnormal 
Aβ42 accumulation are not fully understood, both increased production and decreased degradation have 
been observed (Crouch et al., 2008). Aβ42 are able to adopt many differently shaped aggregates 
including amyloid fibrils (Glabe, 2008) as well as nonfibrillar aggregates that are also termed soluble 
Aβ42 “oligomers”(Haass and Selkoe, 2007). It is not well established which Aβ state is most 
responsible for AD or why. Recent evidence strongly implicates Aβ42 oligomers as the proximal 
pathogenic trigger (De Felice et al., 2008). These oligomers are markedly elevated in the brain and 
cerebrospinal ﬂuid of postmortem AD patients and appear to play a critical role in the synaptic failure 
and memory deﬁcits of early AD (Klyubin et al., 2008). It is therefore important to determine directly 
whether neurons exposed to oligomers undergo pathological changes characteristic of AD brain. In the 
current study, we sought to verify the effects of both oligomers and aggregated Aβ42 peptides on gene 
expression, protein level and enzyme activity in vitro. The cell culture model chosen for this 
investigation was the human SH-SY5Y neuroblastoma cell line. These cells show the most common 
neurobiochemical (e.g. enzymes like dopamine β-hydroxylase, acetylcholintransferase, etc. and 
neurotransmitter like dopamine, adrenaline, acetylcholine, GABA) and neurobiological factors (e.g. 
dopamine transporter and receptors, GABAergic receptors, etc.) (Biedler et al., 1978; Ross et al., 
1983) and can be perfectly used as an experimental model to study effects of Aβ42 oligomers and 
aggregated Aβ42 peptides. Our main focus lay on treatment effects on -secretase (BACE), glycogen 
synthase kinase 3α (GSK3α), glycogen synthase kinase 3 (GSK3), phosphatidylinisitol-3 kinase 
(PI-3K), insulin degrading enzyme (IDE), insulin receptor substrate 1 (IRS1), insulin receptor (INSR) 
and monoamine oxidase B (MAO-B). They are all already known to be involved in the pathology of 
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AD: BACE is the first protease in the processing of amyloid precursor protein (APP) leading to the 
production of Aβ42 in the brain, therefore it is one recent target for therapeutic treatment of AD (Ghosh 
et al., 2011). Over-activity of GSK3 accounts for memory impairment, tau hyperphosphorylation, 
increased A production and local plaque-associated microglial-mediated inflammatory responses; all 
of which are hallmark characteristics of AD (reviewed in (Hooper et al., 2008)). PI-3K has been 
identified as second messenger system providing anti-apoptotic signal to various cell types (Brunet et 
al., 2001). Additionally, neuroprotection against extracellular Aβ42 toxicity is dependent on PI-3K 
pathway (Zhang et al., 2003; Lesne et al., 2005). IDE is a metalloprotease that apart from insulin also 
binds and degrades other substrates, including Aβ42, therefore reduced IDE activity diminishes Aβ 
clearance and contributes to the formation of senile plaques (Mukherjee et al., 2000). Not only for IDE 
insulin and Aβ42 are counterparts, in fact Aβ42 peptides directly compete with insulin for binding to the 
INSR (de la Monte et al., 2009) and INSR dysfunction impairs cellular clearance of neurotoxic 
oligomeric Aβ42 (Zhao et al., 2009). MAO-B activity is significantly increased in AD patients (Gotz et 
al., 1998; Grünblatt et al., 2005) and inhibition of MAO-B has a neuroprotective effects for AD 
(reviewed in (Riederer et al., 2004). 
Material and Methods 
Cell culture  
SH-SY5Y cells were bought from European Collection of Cell Cultures and grown in buffered 
Dulbecco`s modified Eagle medium (DMEM/F-12) (Pan Biotech GmbH, Aidenbach, Germany) 
supplemented with 10% fetal bovine serum  and 0.1% gentamycin (50 mg/ml) (Life technologies, 
Darmstadt, Germany) in a humidified incubator (5% CO2) at 37°C.  
Preparation of soluble and aggregated Aβ42 
The preparation of the Aβ42 peptide was modified according to Dahlgren (Dahlgren et al., 2002). 
500mg of freeze-dried Aβ42 (Millipore, Schwalbach, Germany) was dissolved in 1,1,1,3,3,3 
hexafluoroisopropanol (HFIP) to a concentration of 1mM and incubated for one hour at room 
temperature. Subsequently, the HFIP was removed by using a vacuum centrifuge and the peptide film 
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was dissolved in dry dimethyl sulfoxide (DMSO) to a final concentration of 5mM. For aggregated 
Aβ42 peptides, the solution was diluted with 10mM HCl and stored for 7 days in the incubator at 37°C. 
The test concentrations of both the soluble and the aggregated Aβ42 were finally diluted with normal 
cell culture medium. 
Cell treatment with Aβ42 
For western blot (WB), enzyme linked immunosorbent assay (ELISA), fluorescent ELISA and 
quantitative real-time polymerase chain reaction (QRT-PCR) , SH-SY5Y cells were treated with 
varying concentrations of soluble and aggregated Aβ42 (see preparation above) (0, 5, 1, 2,5 and 10µM), 
or purified DMSO or HCl as a control, by adding it in the right concentration to the culture medium. 
The reaction was stopped after 48 h and cells were trypsinized for further investigations. 
Cytotoxicity  
To determine a possible toxic effect of Aβ42 on the cells, the CytoTox-Glo
TM
 test from Promega 
(Mannheim, Germany) was performed. For testing the cytotoxicity effect, 10.000cells/ml  per well 
were cultivated for 24 hours at 37°C in 5% CO2 saturation in the incubator, so that the cells could 
adhere to the bottom of the wells. Afterwards cells were treated with soluble or aggregated Aβ42 in a 
concentration of 0.1, 0.5, 1, 2, 3, 5, 10, 20, 50 and 100 µM. Reaction was measured 48h later. 
RNA extraction and QRT-PCR 
Total RNA was extracted from SH-SY5Y cells using the RNeasy Plus MiniKit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Total RNA (500 ng) was reverse transcribed 
using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Munich, Germany). QRT-PCR was 
performed using an iCycler iQ
TM
 Real Time PCR Detection System (Bio-Rad) and the SYBR-Green 
detection method. The QRT-PCR reaction was optimized according to the manufacturer’s instructions. 
QuantiTech Primer assays for -actin (ACTB; QT00193473), glyceraldehyde-3-phosphate dehdroge-
nase (GAPDH, QT01192646), ribosomal protein L13A (RPL13A; QT00089915), peptidylprolyl 
isomerase A (PPIA, QT01866137), -secretase (BACE, QT00084777), glycogen synthase kinase 3α 
(GSK3α, QT00075306), glycogen synthase kinase 3 (GSK3ß, QT00057134), phosphatidylinisitol-3 
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kinase (PI-3K,  QT00035175), insulin degrading enzyme (IDE, QT00080773), insulin receptor 
substrate 1 (IRS1, QT00074144) and  insulin receptor (INSR, QT00082810) were purchased from 
Qiagen (Hilden, Germany). ACTB, GAPDH, RPL13A and PPIA were used for normalization 
according to GeNorm (Vandesompele et al., 2002). The amplified transcripts were quantified using the 
comparative threshold cycle (Ct) analyzed using the BioRad iCycler iQ program.  
Western blot  
Western blotting was used to detect changes in the protein levels of Insulin receptor (IR) β subunit in 
SH-SY5Y cells. To determine total protein amount of each sample, Bradford protein assay was 
conducted (Sigma-Aldrich, Schorndorf, Germany). Samples (50µg of total protein, denaturated with 
dithiothreitol) were separated on 4-12% Bis-Tris gel and transferred onto nitrocellulose membranes 
(Life technologies, Darmstadt, Germany). Protein of interest was detected using its speciﬁc antibodies: 
rabbit anti-IRβ (antibody) (1:250, Santa Cruz, Heidelberg, Germany). Following blocking the 
membrane for one hour at room temperature (5% blocking milk in TBS-Tween) and afterwards 
incubation with primary antibody at 4°C overnight, membranes were incubated with HRP conjugated 
secondary antibody (1:15.000, Sigma-Aldrich, Schorndorf, Germany) for one hour at room 
temperature. The IRβ protein immunoreactive bands were detected using the enhanced 
chemiluminescence (ECL) detection plus system from GE Healthcare (Freiburg, Germany) and 
quantiﬁed using ImageJ software without modifying picture properties (e.g. gain, colour or contrast). 
For comparison the values of β-actin, as a house keeping protein, were used. The membranes were 
stripped to remove the attached antibodies. It was followed by one-hour incubation in 5% BSA 
blocking solution at room temperature. The murine β-actin antibody (1:5000, Santa Cruz, Heidelberg, 
Germany) was already linked with HRP and was detected and quantified like IRβ protein.  
Enyzme linked immunosorbent assays 
The Invitrogen (Darmstadt, Germany) GSK-3β kit is a solid phase sandwich enzyme linked 
immunosorbent assay (ELISA) and was used to detect and quantify the level of total GSK-3β protein 
and of GSK-3β protein phosphorylated at serine residue 9. Samples were prepared according to 
JNT Original paper     Bartl, et al. 
manual. Detected protein amount was normalized with total protein amount of used samples, as 
detected via Bradford protein assay (Sigma-Aldrich, Schorndorf, Germany). 
Enzyme activity 
MAO-B enzyme activity was measured by using amplex red monoamine oxidase assay kit (Life 
technologies, Darmstadt, Germany). 50µg of total protein (detected via Bradford protein assay) of 
homogenized SH-SY5Y cells was diluted in reaction buffer and varying concentrations of soluble and 
aggregated Aβ42 (see preparation above) (0.5, 1, 2.5 and 10µM) were added. After 30 minutes 
incubation at 37 °C, 100μl substrate mix was added and again incubated for 1 hour at 37°C. The 
endpoint measurement was done in a fluorescence multi plates meter (Novostar) at an excitation of 
542 nm and an emission of 590 nm. 
Statistical analysis 
Statistical analyses of the WB, ELISA and QRT-PCR data were performed using StatView for 
Windows (SAS Institute Inc., version 5). Statistical tests included analysis of variance (ANOVA) with 
post-hoc Scheffé Test. Significance was set as p<0.05. For a better comparison of the data, we 
normalized the results and converted the data into percentages. The control group was set as 100%. 
The results represent at least 3 repeated experiments with around 4 internal repeats. 
Results 
Soluble and aggregated species of Aβ42 were prepared as described above and controlled via electron 
microscopy (shown in supplementary figure 1). Avoiding neural cell death, we tested a wide range of 
Aβ42 µM doses (0-100µM) before cell treatment and used just the nontoxic range from 0-10µM for 
this study. Concentration of over 20M aggregated A42 showed significant cell toxicity, while for 
soluble form only a trend to toxicity was observed (supplementary figure 2). 
Gene expression  
BACE, GSK3α, GSK3β, PI-3K, IDE, IRS-1 and INSR were the investigated genes. After gene 
expression analysis we could detect two genes with significant differences between treated and 
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untreated cells. GSK3β was significantly up-regulated after cell treatment with 1 and 2µM (+362% 
p<0.05; +357 p<0.05) of soluble Aβ42 and we could detect a tendency of higher gene expression after 
treatment with 1, 2, 5 and 10µm of the aggregated Aβ42 (Table 1). The second gene revealing 
statistically significant results was the INSR. Treatment with 5 and 10µM of soluble peptides tended to 
result in a lower INSR gene expression compared to untreated cells while on the other hand, treatments 
with 1µM of the aggregated peptides tended to result in a higher expression and treatment with 5 and 
10µM even led to a significant overexpression of INSR (+183 p<0.05; +201 p<0.05; Table 1). Based 
on these results we further investigated the protein expression of these two genes in order to examine 
whether the differences influence gene transcription. 
Protein level  
After SH-SY5Y cells were treated with all doses of soluble Aβ42, significantly more GSK3β protein 
levels (30-45%) was detectable compared to the control cells (p<0.01, figure 1a), which confirm the 
gene expression data of GSK3β. Treatments with aggregated peptides did not show any significant 
effects on GSK3 total protein levels in non of the used doses (figure 1A). Because GSK3β is a kinase 
enzyme, that when phosphorylated at serine residue 9 becomes inactive, we investigated the 
phosphorylated form of this protein to affirm whether it is more or less active after Aβ42 treatment to 
the cells. We calculated the ratio between total amount of GSK3 protein and its phosphorylated form, 
which represents the enzyme activity (figure 1B). Remarkably, not only the total protein amount of 
GSK3β was statistically significantly increased after treatment with soluble peptides, but there was 
also a significant detectable enhancement of the enzyme activity under this condition (145%-231% 
more activity in all used dosages compared to untreated cells; 0.01<p<0.05; figure 1B). On the other 
hand the enzyme activity did not alter after treatment with aggregated peptides (figure 1B).  
The gene expression data of INSR demonstrated already a tendency for reduced expression after 
treatment with soluble peptides (table 1), which resulted in significantly decreased total amount of IR 
after treatment with 0.5, 1 and 2µM of soluble Aβ42 (50%-60% less total IR protein amount 
compared to untreated cells, p<0.05; figure 2). On the other hand, in the gene expression analysis a 
significant overexpresion of INSR after treatment with aggregated peptides was observed (table 1), 
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which was confirmed only at 1µM aggregated peptide treatment for the total IR protein expression. 
At 1µM of aggregated Aβ42 we could detect 60% more IR compared to control cells (p<0.05; figure 
2).  
Enzyme activity 
MAO B enzyme activity was significantly reduced after cell homogenate treatment with 1, 2, 5 and 
10µM of soluble Aβ42 peptides (18%-30% less activity, p<0.01; figure 3). In contrast the aggregated 
peptides enhanced the enzyme activity with significant results at 1, 2 and 5µM of aggregated peptide 
(30%-40% more activity compared to control; p<0.01; figure 3).  
Discussion 
AD is one of the most common form of dementia in the elderly (Blennow et al., 2006) and although 
increasing factors are found to be involved in AD, excessive Aβ42 deposition is still considered to play 
a major role in this disease. Aβ42 is derived from the APP by the action of two aspartyl proteases, β- 
and γ-secretases. So accrued Aβ42 molecules tend to aggregate to form  soluble oligomers, protoﬁbrils, 
and β-amyloid ﬁbrils, which have been suggested to cause neuronal dysfunction in the brains of AD 
patients (reviewed in (Ono and Yamada, 2011)). However, it is not well established which Aβ42 state 
is most responsible for AD or why. In this study we verified, which effects Aβ42 oligomers and 
aggregated Aβ42 peptides have on gene expression, protein level and enzyme activity of the insulin  
and APP pathways in vitro. In particular, we have observed a strong influence of the soluble form of 
Aβ42 peptides on GSK3β gene expression as well as on its protein level and activity. It has been 
already postulated that GSK3β activity might exert a central role in the development of AD (Hooper et 
al., 2008). GSK3β activity was implicated in tau phosphorylation, APP processing, Aβ42 production 
and neurodegeneration (Balaraman et al., 2006; Hooper et al., 2008). Our finding of increased GSK3β 
gene/protein expression and activity points to the fact, that GSK3 might be a crucial element in the 
Aβ42-triggered molecular cascade leading to potential neurodegeneration. The observed effect of Aβ42 
oligomers on GSK3β might be mediated by interaction with different receptors, but mainly with the 
interaction of INSR. It was already shown that Aβ42 oligomers interact with neuronal INSR to cause 
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impairments of the receptor expression and function (Townsend et al., 2007; Zhao et al., 2009). 
Normally, activation of INSR leads to the phosphorylation of PI 3-kinase, which leads to an activation 
of AKT. Once active, AKT enters the cytoplasm where it leads to the phosphorylation and inactivation 
of GSK3 (Jolivalt et al., 2008). Thus, although normal INSR activity helps to defend against the 
accumulation of toxic Aβ42 oligomers, the INSR themselves are vulnerable to oligomer-initiated 
dysfunction. The presented data indicate the fact that this relationship has the potential to generate an 
insidious pathogenic loop. We could observe a significant reduction of INSR gene and protein 
expression after SH-SY5Y treatment with soluble Aβ42 oligomers compared to untreated cells. 
Consistent with the actual finding reported here, our group could already report that in AD patient less 
INSR were found especially in the hippocampal region of the brain (Bartl et al., 2012). Not only an 
impairment of INSR leads to an activation of GSK3β as explained before, also oxidative stress can 
enhance the activity of this kinase (Hernandez and Avila, 2008). In 2004, Riederer et al. already 
reviewed the link between oxidative stress and AD, especially regarding the increased MAO-B 
activity (Riederer et al., 2004). MAO-B is a ﬂavin containing enzyme localized in the outer 
mitochondrial membrane and is responsible for the oxidative deamination of neurotransmitters 
(noradrenaline, dopamine and serotonin) and exogenous amines. During its catalytic activity it 
produces hydrogen peroxide formed in the reaction, which is a possible source for oxidative stress. 
Highlighting more the possible link between Aβ42, GSK3 and MAO-B we analyzed the effect of 
soluble and aggregated peptides on MAO-B enzyme activity. Interestingly, the soluble oligomers 
inhibited the enzyme activity significantly, but the aggregated forms of Aβ42 peptides, which are more 
similar to the amyloid plaques within the brain, enhanced the MAO-B activity in a dose dependent 
manner. Although we could find an inhibition of MAO-B activity after soluble peptide treatment, it 
cannot be concluded that these oligomers might be neuroprotective. An increased MAO-B activity was 
found in senile plaques (Saura et al., 1997) and in platelets of AD patients (Gotz et al., 1998), 
therefore our results of enhanced MAO-B activity following treatment with aggregated while not with 
soluble Aβ42 peptides, might indicate the involvement of the fibrillar structures of Aβ42 in the oxidative 
stress cascade known to play an important role in AD (Grünblatt et al., 2005; Grünblatt et al., 2010). 
To our knowledge, this is the first report indicating the direct influence of soluble or aggregated 
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peptides on MAO-B activity in vitro. Our data affirm that there has to be a neurobiochemical link 
between MAO-B and Aβ42. In conclusion, our results suggest that Aβ42 oligomers seem to be more 
involved in cellular mechanisms linked to AD, except in enhancement of MAO-B activity, than the 
aggregated Aβ42 peptides, which is confirmed with the actual literature. AD seem to involve numerous 
mechanisms such as amyloid plaque formation, tau hyperphoshprylation, apoptosis, impairment of 
insulin signaling pathway and oxidative stress, causing neurodegeneration, which means that further 
investigations are necessary to enlighten the molecular mechanism of AD pathogenesis. 
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Figure legends 
Figure 1: Total protein amount of glycogen synthase kinase 3β (GSK3β) and ratio of 
phosphorylated GSK3ß / total GSK3ß after SH-SY5Y treatment with soluble and aggregated 
Aβ42 peptides. A Shown is the percentage of the mean values of total amount of the protein measured 
by a sandwich ELISA . B Shown is the percentage of the mean values of total amount of the protein 
and of phosphorylated protein amount measured by a sandwich ELISA. Reference value (100%) is 
control group with untreated SH-SY5Y cells. For the statistical analysis ANOVA, post-hoc Scheffé 
with a specified significance level of p <0.05 was used. *= p <0.05, ** = p <0.01 versus control. The 
sample size was n = 6-12. 
Figure 2: Total protein amount of insulin receptor (INSR) after SH-SY5Y treatment with soluble 
and aggregated Aβ42 peptides. Shown is the percentage of the mean values of total amount of the 
protein measured by western blot . Reference value (100%) is control group with untreated SH-SY5Y 
cells. For the statistical analysis ANOVA, post-hoc Scheffé with a specified significance level of p 
<0.05 was used. *= p <0.05, ** = p <0.01 versus control. The sample size was n = 6-12. 
Figure 3: Monoamino oxidase B (MAO-B) activity after SH-SY5Y treatment with soluble and 
aggregated Aβ42 peptides. Shown is the percentage of the mean values of enzyme activity measured 
by an amplex red monoamine oxidase assay. Reference value (100%) is control group with untreated 
SH-SY5Y cells. For the statistical analysis ANOVA, post-hoc Scheffé with a specified significance 
level of p <0.05 was used. *= p <0.05, ** = p <0.01 versus control. The sample size was n = 20-38. 
Figure 1: Total protein amount of glycogen synthase kinase 3β (GSK3β) and ratio of phosphorylated 
GSK3ß / total GSK3ß after SH-SY5Y treatment with soluble and aggregated Aβ42 peptides. 
 
 
 
 
 
 
 
Figure 2: Total protein amount of insulin receptor (INSR) after SH-SY5Y treatment with soluble and 
aggregated Aβ42 peptides. 
 
 
 
  
Figure 3: Monoamino oxidase B (MAO-B) activity after SH-SY5Y treatment with soluble and 
aggregated Aβ42 peptides. 
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